Spectrum Pharmaceuticals Initiates Phase 1 Study of a Novel Adjunct to Cancer Chemotherapy
News Feb 11, 2008
Spectrum Pharmaceuticals, Inc. has announced that the first patient has received SPI-1620 in a Phase 1 dose-escalation study. SPI-1620, a highly selective endothelin-B agonist, is being developed as an adjunct to cancer chemotherapy.
The Phase 1 trial is an open label, dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of SPI-1620 in patients with recurrent or progressive carcinoma.
“In preclinical studies, administering SPI-1620 fifteen minutes prior to chemotherapy demonstrated up to 400% increase in drug concentration in the tumors, resulting in increased tumor response,” said Rajesh C. Shrotriya, M.D., President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc.
“We believe that with further clinical development, SPI-1620 has the potential to significantly increase the efficacy of a broad range of chemotherapeutic drugs used for the treatment of solid tumors,” Shrotriya added.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE